Physician profile
Leann Olansky
NPI 1881663698
$934.52
in general payments reported to CMS, 2019-2025
9 companies · $53.62 in 2025
The $53.62 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $239 · 2022: $29.39 · 2023: $174 · 2024: $65.07 · 2025: $53.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $292.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $536.54 | 2019-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $124.87 | 2023 | Dexcom G7 Gss (161) |
| Tandem Diabetes Care, INC. | $120.74 | 2020 | |
| Abbott Laboratories | $57.28 | 2024-2025 | Freestyle Libre 3 |
| Averitas Pharma INC. | $29.11 | 2023 | Qutenza |
| Organogenesis INC. | $23.11 | 2024 | Apligraf |
| Advanced Accelerator Applications | $18.18 | 2019 | |
| Merck Sharp & Dohme LLC | $12.36 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leann Olansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.